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ABSTRACT  
Major surgery is associated with an increased risk of venous thromboembolism, thus the 
application of mechanical or pharmacologic prophylaxis is recommended. The incidence of venous 
thromboembolism in patients with inherited platelet disorders undergoing surgical procedures is 
unknown and no information on the current use and safety of thromboprophylaxis, particularly of 
low-molecular-weight-heparin in these patients is available. Here we explored the approach to 
thromboprophylaxis and thrombotic outcomes in inherited platelet disorders patients undergoing 
surgery at venous thromboembolism-risk participating in the multicenter SPATA study. 
We evaluated 210 surgical procedures carried out in 155 patients with well-defined forms of 
inherited platelet disorders (venous thromboembolism-risk: 31% high, 28.6% intermediate, 25.2% 
low, 15.2% very low). The use of thromboprophylaxis was low (23.3% of procedures), with higher 
prevalence in orthopedic and gynecological surgeries, and was related to venous 
thromboembolism-risk. The most frequently employed thromboprophylaxis was mechanical and 
appeared to be effective, as no patients developed thrombosis, including patients belonging to the 
highest venous thromboembolism-risk classes. Low-molecular-weight-heparin use was low 
(10.5%) and it did not influence the incidence of post-surgical bleeding or of antihemorrhagic 
prohemostatic interventions. Two thromboembolic events were registered, both occurring after 
high venous thromboembolism-risk procedures in patients who did not receive 
thromboprophylaxis (4.7%).  
Our findings suggest that venous thromboembolism incidence is low in patients with inherited 
platelet disorders undergoing surgery at venous thromboembolism-risk and that it is predicted by 
the Caprini score. Mechanical thromboprophylaxis may be of benefit in patients with inherited 
platelet disorders undergoing invasive procedures at venous thromboembolism-risk and low-
molecular-weight-heparin should be considered for major surgery. 
 
SUMMARY 
- We evaluated the incidence of venous thromboembolism (VTE) and the use of 
thromboprophylaxis in patients with inherited platelet disorders (IPD) undergoing surgery 
- VTE incidence is low in patients with IPD and is predicted by the Caprini score. Mechanical 
thromboprophylaxis may be of benefit and LMWH should be considered for major surgery 
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INTRODUCTION 
Venous thromboembolism (VTE) is a severe and sometimes lethal complication of major surgery 
triggered by the release of pro-thrombotic substances from injured tissues, immobilization, 
medical comorbidities and favored by thrombophilia. It occurs in 20-25% of patients undergoing 
general surgery and in up to 60% of patients undergoing orthopedic surgery not receiving 
antithrombotic prophylaxis 
1-4
.  
VTE can be largely prevented by the use of mechanical and/or pharmacologic antithrombotic 
prophylaxis. Mechanical thromboprophylaxis with compressive stockings or intermittent 
pneumatic compression devices reduces the risk of VTE by 64% and 60%, respectively 
5, 6
, while 
pharmacologic thromboprophylaxis with low molecular weight-heparin (LMWH) reduces VTE risk 
by 75%, although it doubles the risk of major bleeding 
4, 7
. A meta-analysis of clinical trials 
comparing mechanical vs pharmacologic thromboprophylaxis in general and orthopedic surgery 
found a 80% higher risk of DVT (including asymptomatic and distal DVT) among patients treated 
with mechanical thromboprophylaxis but a 57% lower risk of major bleeding 
8
. Moreover, a 
systematic review comparing intermittent pneumatic compression with elastic compressive 
stockings in surgical patients found a prevalence of deep vein thrombosis (DVT) of 2.9% in the first 
group and of 5.9% in the second 
9
. Recently, it has been observed that the addition of mechanical 
to pharmacologic thromboprophylaxis does not provide further benefit
10
. 
The risk of VTE associated with surgery changes according to a series of variables. The American 
College of Chest Physicians (ACCP) evidence-based clinical practice guidelines classify surgical 
interventions into three VTE-risk categories depending on the type of procedure
3
. Moreover, 
individual VTE-risk can be estimated more accurately based on patient characteristics and risk 
factors using appropriate scores, one of the most widely used of which is the “Caprini score” 
which subdivides patients into four risk categories 
11
. 
The incidence of VTE in patients with inherited platelet disorders (IPDs) undergoing surgical 
procedures at VTE-risk is unknown, and no clinical trials or large case series have ever been 
reported, although several reports suggest that these patients may not be protected from 
thrombosis
12-15
, especially when considering that some prophylactic antihemorrhagic treatments 
currently used in these patients for the preparation to surgery, like platelet transfusions or rFVIIa 
16, 17
, increase VTE-risk 
12, 18, 19
.  
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Moreover, no systematic studies on the use of thromboprophylaxis in patients with IPDs 
undergoing surgery have been carried out, and no information on the safety of the prophylactic 
administration of LMWH to IPD patients is available, although isolated reports on the safe 
administration of anticoagulants to IPD patients have been published
20-24
. 
Recently, the large retrospective, multicenter SPATA study evaluated bleeding complications and 
management of surgery in patients with IPD 
17
. In the present study we evaluated the approach to 
thromboprophylaxis adopted for the IPD patients undergoing surgery at VTE-risk participating in 
the SPATA study. In particular, we aimed to assess current clinical decisions on VTE prevention, to 
estimate postoperative VTE risk and to evaluate the association between the use of mechanical or 
pharmacologic thromboprophylaxis and clinical VTE incidence and surgical bleeding in IPD. 
 
METHODS 
Study population 
In the current sub-study we included all the surgical procedures performed in patients enrolled in 
the SPATA study according to well-defined laboratory and/or molecular genetic criteria
17,25-27
 for 
whom thromboprophylaxis should have been considered according to current guidelines, 
including major and minor invasive interventions
3, 11,28
. The decision to apply thromboprophylaxis 
was made by the attending physicians on an individual basis. Patients under 16 years of age were 
excluded due to the lower intrinsic VTE-risk in younger age
29, 30
. Surgery definitions were 
previously reported
17
.  Given the significant in situ thrombotic risk of central venous catheter 
insertion interventions 
31
, these were also considered in the analysis as minor procedures with 
high local thrombotic risk.  
A 48-item structured questionnaire on VTE-risk, thrombotic and bleeding events and 
antithrombotic prophylaxis had to be filled in for each at-risk procedure. Individual bleeding risk 
was estimated according to the type of IPD and previous individual bleeding history as assessed by 
the WHO-bleeding score
 17
. 
The Institutional Review Board of the coordinating center approved this sub-study (CEAS Umbria, 
Italy, Approval n. 13138/18). 
For further details see the Supplemental Data. 
 
Thromboembolic risk  
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VTE-risk associated with the individual surgical procedures was estimated using the Caprini Score 
32,33
. The enrolled procedures were subdivided into four classes of risk depending on the Caprini 
score. Surgical procedures were also classified according to procedure-related VTE-risk in three 
groups as suggested by the 2008 ACCP
3
. Both the Caprini and the procedure-related VTE-risk 
scores were centrally calculated based on the replies given by the participating investigators to the 
48-item questionnaires. Further details are in the Supplemental Data. 
 
Thrombotic outcomes 
Thrombotic outcomes were defined as any symptomatic thrombosis (deep venous, including 
distal, and superficial) and/or pulmonary embolism occurring within one month after surgery. For 
details see Supplemental Data. 
 
Bleeding outcomes 
Previous bleeding history was assessed using the World Health Organization (WHO) bleeding 
assessment scale (WHO-BS)
34
, while excessive bleeding occurring after surgery and the rate of 
success of emergency treatment of post-surgical bleeding were classified as previously described 
17
. Additionally, data about the need of blood transfusion after surgery were collected. 
Participating investigators were asked to provide informations about bleeding outcomes occurred  
both during and immediately after hospitalization for surgery. 
 The outcome of emergency treatment of excessive post-surgical bleeding was classified as 
successfully controlled, not responsive to treatment or re-bleeding 
17
.  
 
Statistical analysis 
As this was a pilot, exploratory study without any a-priori test hypothesis, we did not perform a 
formal sample study analysis. Variables not normally distributed were reported as medians and 
interquartile ranges (IQRs), and differences were tested using the Mann–Whitney U test or the 
Kruskal–Wallis analysis of variance (ANOVA) test. Data are shown as medians and interquartile 
ranges (IQRs).  Categorical variables were analysed using the Chi-square test. A Cochrane-Armitage 
test of trend was used to evaluate the correlation between dichotomous and ordinal variables. 
Logistic regression analysis was performed to identify predictors of excessive post-surgical 
bleeding, of heparin use, of the need for anti-hemorrhagic interventions and of the success of 
post-surgical bleeding management. All analyses were performed using SPSS version 22.0 (IBM 
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Corporation, Armonk, NY, USA). 
 
RESULTS 
Patient characteristics 
Out of the 829 surgical procedures included in the SPATA study, 210 carried out in 133 patients 
met the inclusion criteria, 132 of which were performed in females (63.8%),  with 31 patients 
undergoing more than one procedure. Of these interventions, 110 (52.4%) were carried out in 66 
patients with 14 different forms of IPFD, and 100 (47.6%) in 67 patients with 7 different forms of 
IPND (Supplementary Table 1). Median age at surgery was 45 years (IQR 29-56; min 17, max 88). 
Two patients (0.9%), aged 19 and 26 years undergoing one procedure each, were heterozygous 
carriers of FV Leiden mutation, although it should be considered that no systematic search for 
thrombophilic genetic mutations was made in the enrolled population; 11 procedures (5.2%) were 
performed in patients with a history of malignancy (median age 55 years, IQR 52-79), and 4 (1.9%)  
in patients with chronic obstructive pulmonary disease (COPD) (median age 51 years, IQR 42-59). 
Sixty-five interventions (31%) were performed in patients with a Caprini score ≥ 5, 60 (28.6%) in 
patients with a score between 3 and 4, 53 (25.2%) in patients with a score between 1 and 2, and 
32 (15.2%) in patients with a score of 0. Median age was 32 years (IQR: 20-49) for patients with a 
score of 0, 35 (IQR 27-46) for patients with a score of 1-2, 46 (IQR 32-60) for patients with a score 
of 3-4, and 52 (IQR 41-61) for patients with a score ≥5. Sixty-one interventions (29%) (32 in 
patients with IPFD and 29 in patients with IPND) were low-risk, 114 (54%) (55 in patients with IPFD 
and 59 in patients with IPND) were intermediate-risk, and 35 (17%) (23 in patients with IPFD, 12 in 
patients with IPND) were high-risk.
3
 In low-risk procedures, the median age was 49 years (IQR 33-
58), in intermediate-risk 37 years (IQR 28-53), and in high-risk 53 years (IQR 33-62). 
 
Type of surgery and antithrombotic prophylaxis 
Seventy-two procedures were abdominal (34.3%), 55 gynecological (26.2%), 41 orthopedic 
(19.5%), 14 urological (6.7%), 10 cardiovascular (4.8%), 9 thoracic (4.3%), 6 neurosurgical (2.9%), 
and 3 spine surgeries (1.3%). Ninety interventions were major surgery (43%) while the other 120 
procedures (57%) were minor invasive interventions followed by immobilization for ≥ 24 hours. 
The oldest group of patients were those undergoing urological interventions (median age 58 
years), while the youngest patients underwent gynecological surgery (median age 36 years). 
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Malignancy was most frequent in patients undergoing thoracic surgery (Table 1). Of the overall 
210 surgical procedures, 89% were elective and 11% urgent. 
The Caprini score was higher in patients undergoing cardiovascular interventions and lower for 
abdominal interventions (Table 1). 
Out of 210 surgical procedures, 49 (23.3%) were managed with thromboprophylaxis; of these 27 
(55.1%) were managed with mechanical thromboprophylaxis alone, using either compression 
stockings (26 procedures) or intermittent pneumatic compression (one procedure), 19 (38.8%) 
with LMWH alone, and 3 (6.1%) with both methods (mechanical and pharmacologic). 
Of the 49 interventions managed with thromboprophylaxis, 13 were orthopedic (26.0%), 12 
gynecological (24.5%), 7 abdominal (14.3%), 7 thoracic (14.3 %), 7 urological (14.3%) and 3 neuro-
spinal (6%). LMWH prophylaxis was adopted in 22% of the orthopedic procedures, 12.7% of 
gynecological, 11% of thoracic, 11% of neuro-spinal surgery, 7.1% of urological and 4.2 % of 
abdominal (Table 1, Figure 1). The two patients carriers of FV Leiden mutation were both at 
intermediate VTE-risk and had a low WHO-BS (0 and 2, respectively). They both underwent 
gynecological surgery without thromboprophylaxis and did not develop VTE. Patients with a 
history of malignancy were all classified at intermediate VTE-risk, and their median WHO-BS was 2. 
In these patients, heparin was used in 4 procedures mechanical thromboprophylaxis in 5 and no 
prophylaxis in 2. No VTE was recorded in this population (Supplementary table 2).   
Of the procedures at high VTE-risk according to the Caprini risk stratification (n=65)
33
, 
thromboprophylaxis was adopted in 22 (33.8%) (LWMH in 14, mechanical in 6, and both in two) 
with no VTE events, while in 43 it was not adopted. Regarding procedures at intermediate VTE-risk 
(n= 60), thromboprophylaxis was used in 15 (25%) (mechanical in 11 and pharmacologic in 4), 
while of the procedures at low VTE-risk (n=53) thromboprophylaxis was used in 10 (18.9 %) (9 
mechanical, 1 both mechanical and pharmacologic), and of the procedures at very low VTE-risk 
(n=32), thromboprophylaxis was used in only 2 patients (6.2%) (1 mechanical, 1 pharmacologic). 
According to the procedure-related VTE-risk stratification
3
, 35 high-risk procedures, 114 
intermediate-risk and 61 low-risk, were performed. Thromboprophylaxis was adopted in 42% 
(nine pharmacologic and six mechanical) of the high-risk procedures, in 21% (six pharmacologic, 15 
mechanical and three both) of the intermediate-risk and in 16.4% (four pharmacologic and six 
mechanical) of the low risk procedures.  The choice of using LMWH, was significantly associated 
with the Caprini risk class (p< 0.001 and p= 0.002 respectively) (Supplementary Table 3) and with 
the procedure-related VTE-risk class (p= 0.007 and p= 0.009, respectively) (Figure 2A). The use of 
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thromboprophylaxis with LMWH was similar between elective and urgent procedures: 10.2% vs 
13% respectively (p=ns). 
Older age also independently predicted the use of pharmacologic thromboprophylaxis. In fact, 
LMWH-treated patients were significantly older (median age: 67 vs 42 years; p< 0.01) and had a 
higher median Caprini score (8 vs 4; p < 0.01) than non-treated patients (Table 2). Additionally, 
history of cancer was more frequent in heparin users than in non-users (18% vs 3.2%, p= 0.018).  
On the contrary, neither the WHO-BS nor gender distribution (both in IPFD and IPND) were 
significantly associated with LMWH use. 
Mechanical prophylaxis was applied with graduated compression stockings in 30 procedures (14%) 
and with intermittent pneumatic compression in 1 procedure (0.47%), while pharmacologic 
prophylaxis was undertaken with enoxaparin in 18 procedures (8%), tinzaparin in 1 (0.47%), 
dalteparin in 1 (0.47%), and in two cases (0.95%) type was not specified. Enoxaparin was 
administered at a median dose of 4000 IU/day (IQR 2000-5000 IU/day) for a median duration of 15 
days (IQR 7-18), starting on the day of surgery. The use of LMWH, as well as the use of any 
thromboprophylaxis, increased over time during the observation period covered by the study 
(LMWH: OR 2.5; 95% CIs 1.31-4.96; any thromboprophylaxis: OR 1.4; 95% CIs 0.98-2.08) (Figure 3). 
Thromboprophylaxis (pharmacologic and/or mechanical) was more common in patients with IPFD 
compared with those with IPND (34.5% vs 11% p<0.01) due to the greater use of mechanical 
thromboprophylaxis in the former (24% vs 3%; p <0.01), even if there was no difference in VTE-risk 
between the two groups. LMWH was administered in 10% of procedures carried out in patients 
with IPND (10 procedures), and in 10.9% of those carried out in patients with IPFD (12 
procedures).  
None of the patients affected by biallelic Bernard Soulier syndrome (bBSS) (n=11) and Glanzmann 
thrombasthenia (n=5) received pharmacologic thromboprophylaxis. This finding probably reflects 
the perception that the VTE-risk of these patients is low, as suggested by previous reports
14 
and 
fear of bleeding. In IPND, LMWH was neither administered in patients with ACTN1-related 
thrombocytopenia (n=5) nor in the only patient with X-linked thrombocytopenia (Supplementary 
Table 1). Median platelet count of the overall IPD population before surgery was 158 x 10
9
/L (IQR: 
120-287 x 10
9
/L) in procedures followed by LMWH vs 120 x 10
9
/L (IQR: 8-163) in those where 
LMWH was not administered (p= n.s). 
 
Thrombotic outcomes 
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Two thromboembolic events were recorded (0.95% of all interventions), both occurring in patients 
who did not receive thromboprophylaxis (3.5% of non-prophylaxed procedures). One was a 
pulmonary embolism (PE) in a bBSS patient who underwent mitral valve surgery, the other a 
femoral DVT in a Glanzmann thrombasthenia (GT) patient occurring after the placement of a 
central venous femoral catheter for blood transfusions. Both patients were at high VTE-risk 
33 
(Caprini score 12 and 8, respectively), had received prophylactic platelet transfusions before the 
invasive procedure, and had suffered excessive post-procedural bleeding prompting red blood cell 
transfusions. The patient suffering from PE was a 56-year-old obese woman affected by COPD. She 
was then treated with therapeutic dose enoxaparin, but died in hospital from septic shock, 
disseminated intravascular coagulation and acute respiratory distress syndrome. The patient 
suffering from DVT was a 60-year-old woman and she was then treated with therapeutic dose 
enoxaparin for three months, without bleeding complications and with complete resolution of the 
femoral thrombosis. Both patients had previously undergone major elective surgery without 
thromboprophylaxis and without thrombotic complications. When dividing the included surgeries 
according to procedure-related VTE risk, in two of 35 high-risk procedures (0.7%, both IPFD) a VTE 
event occurred, while in 114 intermediate-risk procedures and 61 low-risk procedures no VTE 
occurred. 
 
Bleeding outcomes 
The percentage of patients who suffered from excessive bleeding after surgery was not 
significantly different in LMWH users compared with non-users (4/22: 18.2% vs 46/188: 25.8%, p= 
0.5) and no significant difference in bleeding duration after surgery was found between heparin 
users and non-users (Table 2). The rate of excessive bleeding was instead significantly higher in 
urgent (45.5%) than in elective (22.5%) procedures (p<0.05). 
Also the need of post-surgical blood transfusions did not differ between heparin users and non 
users (18% vs 19%, p= 0.51) as well as the use of post-surgical anti-hemorrhagic interventions. In 
57 cases emergency treatment of post-surgical bleeding was required (27,1%), with platelet 
transfusions administered in 38 procedures, anti-fibrinolytic agents in 9, DDAVP in 1, recombinant 
FVII in 1, other not specified treatment in 6,  and combination therapy with anti-fybrinolytic and 
DDAVP in 2. 
Thromboprophylaxis did not predict the need of post surgical anti-hemorrhagic intervention while 
the bleeding history did (Supplementary table 4). Finally, heparin use was not significantly 
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associated with the rate of success of emergency treatment of excessive post-surgical bleeding, 
although percentages of cases with treatment failures were numerically higher in LMWH users 
than in non-users (19% vs 7%; OR 2.05, CIs: 0.496-8.536, p= 0.321) (Table 2, Supplementary table 
5). Preoperatory prophylactic prohemostatic treatment was adopted in 125 procedures (59%), in 
78 with platelet transfusions, in 9 with anti-fibrinolytic agents, 6 with DDAVP, 3 with activated 
recombinant FVII and 3 with a not-specified agent, in 12 with anti-fibrinolytic agents  and DDAVP,  
in 6 with platelet transfusions, anti-fibrinolytic and DDAVP in combination, in 4 with platelet 
transfusions and anti-fibrinolytics in combination, in 2 with platelet transfusions and DDAVP in 
combination, in 1 with antifibrinolytic agents and a not-specified agent combination, in 1 with 
platelet transfusions and not-specified agent combination. Thromboprophylaxis with LMWH was 
adopted in 10 procedures (11.8%) not managed with preoperatory prohemostatic prophylaxis and 
in 12 (9.6%) of those managed with preoperatory thromboprohylaxis (p=0.651). 
 
DISCUSSION  
Our data show that the current use of thromboprophylaxis in patients with IPD undergoing 
surgery at VTE-risk is low, probably due to fear of bleeding complications and to the belief that 
these patients are protected from VTE. In the general population the prevalence of pharmacologic 
thromboprophylaxis use has been estimated to be 17.7% in neurosurgery, 27% in abdominal 
surgery, 50% in gynecological surgery, 52% in cardiovascular surgery, 67% in urological surgery, 
91% in orthopedic surgery, and 98% in thoracic surgery 
35-38
, while in our IPD population it was 0% 
in cardiovascular surgery, 9% in abdominal surgery, 11% in neuro and spinal surgery, 21.8% in 
gynecological surgery, 31.7% in orthopedic surgery, 50% in urological surgery, and 77% in thoracic 
surgery. In IPD patients, as expected, the most frequently employed thromboprophylaxis was 
mechanical, principally with elastic compression stockings. In otherwise healthy subjects 
undergoing general and orthopedic surgery the use of compression stockings was shown to exert 
a significant protective effect against VTE compared with no stockings (9% vs 21%, OR 0.35, 95% 
CIs: 0.28-0.43) 
39
. In our IPD population this approach seemed to be effective, as no patients using 
post-surgery elastic compression stockings developed thrombosis, including patients at high risk 
based on the Caprini score.  
In the general population, the risk of surgery-associated VTE in patients not undergoing 
thromboprophylaxis is strongly dependent on the Caprini score, with an incidence lower than 0.5% 
when the score is 0, 3% when the score is 1-2, 5% when the score is 3-4, and ≥ 6% when the score 
12 
 
is ≥ 5
11,33,40
. In our IPD population not receiving thromboprophylaxis, no VTE was observed in 
patients with a Caprini score < 5, while in patients with a Caprini score ≥ 5, symptomatic VTE 
occurred in 4.7% of the procedures. These data could suggest that the incidence of surgery-
associated symptomatic VTE is indeed lower in patients with IPD that in healthy controls, at least 
when the Caprini score is not high. The ACCP guidelines classify surgical interventions in three 
groups depending on the risk of developing VTE: low risk (<10%), including minor surgery and 
interventions not requiring patient immobilization, moderate risk (10-40%), including 
gynecological and urological open surgery, and high risk (risk up to 80%), including hip or knee 
arthroplasty, hip fracture surgery, spinal cord injury and procedures associated with high bleeding 
risk 
3
. In our IPD patients, in the high-risk group
3
 58% of the procedures (21 interventions) were 
performed without prophylaxis and 9.5% of these were followed by VTE, while no VTE events 
were observed in moderate or low-risk procedures carried out without thromboprophylaxis. Of 
the two thromboembolic events recorded, one was observed in a GT patient undergoing a femoral 
vein catheter insertion and the other in a bBSS patient undergoing mitral valve surgery, both with 
a high individual VTE-risk (Caprini score of 8 and 12, respectively) and not receiving any 
thromboprophylaxis. Interestingly, the latter is, to our knowledge, the first case of VTE described 
in a bBSS patient. Pharmacologic thromboprophylaxis with LMWH was adopted in only 10% of all 
surgical procedures at VTE-risk in our IPD population. The use of thromboprophylaxis with LMWH 
increased over the observation period covered by the study, reflecting the increased awareness of 
the thrombotic risk of surgical procedures and of the efficacy of pharmacologic 
thromboprophylaxis. When heparin thromboprophylaxis was applied, its use did not seem to be 
guided by the assessment of the individual bleeding risk, but rather by the thromboembolic risk. 
Indeed, the Caprini score was strongly and independently associated with heparin use in our case 
series. No VTE was observed in patients undergoing LMWH prophylaxis, including in those 
belonging to the highest VTE-risk categories according to both the Caprini and procedure-related 
VTE scores. 
LMWH use was neither associated with an increased rate of excessive post-surgical bleeding nor 
with enhanced need for post-surgical antihemorrhagic intervention. Also the use of preoperative 
anti-hemorragic prophylaxis was similar in patients treated or not with LMWH. Thus, our results 
could suggest that thromboprophylaxis with LMWH may be safer than anticipated in IPD patients. 
On the other hand, it should be pointed out that although LMWH did not significantly affect the 
success rate of emergency treatment of post-surgical bleeding, a numerically higher number of 
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insuccesses was observed in patients treated with LMWH. Thus, caution should be taken when 
deciding about LMWH use for IPD patients, especially for those at higher bleeding risk (e.g. more 
severe forms and/or patients with higher WHO bleeding scores). The use of post-surgical 
thromboprophylaxis with LMWH and the rate of VTE were similar between elective and urgent 
procedures, while the rate of excessive post-surgical bleeding was higher in urgent than in elective 
procedures, as expected. 
Our study has several limitations. First, we only looked for symptomatic VTE, thus the incidence of 
total VTE may have been significantly underestimated due to the lack of a systematic instrumental 
diagnostics search of these events during post-surgical follow-up. Indeed, no calf or distal vein 
thrombosis was reported and the latter could have been overlooked, due to the low clinical 
expressivity and difficulty of diagnosis. However, possible underestimation of distal DVT may not 
significantly diminish the clinical relevance of our observations because untreated distal DVT is 
associated with a low risk of proximal propagation and PE
32
. Second, the retrospective nature of 
our study does not allow for definitive conclusions about the impact of heparin use on bleeding in 
patients with IPD. However, the collection of hemorrhagic post-surgical events was the main aim 
of our study and great emphasis was given to careful evaluation of their occurrence. Moreover, 
the observational multicenter nature of our study, as already observed for other registries of 
populations with VTE, allowed us to gather a large patient series in an area difficult to explore with 
clinical trials, like subjects at high bleeding risk
41
. Indeed, interventional clinical trials generally 
exclude patients at bleeding risk, limiting the generalizability of the evidence. Registries have been 
helpful for improving our understanding of the epidemiology, pattern of care and outcomes in 
such patient subgroups
41
. 
Third, our study has a relatively small sample size and it involves a rather heterogeneous 
population undergoing a wide range of interventions performed over a fairly broad time period, 
thus limiting the strength of our results compared with studies carried out in the general 
population, especially when subgroup analyses are concerned. Although this is true, a case series 
of over 200 procedures carried out in rare-disease patients is not negligible in this clinical context, 
if one considers that phase III studies on LMWH prophylaxis in high-risk surgery and trauma have 
included between 100 and 440 patients
42-45
.  
Despite the above limitations, to the best of our knowledge this is the first study which explored 
VTE-risk of surgical procedures in a large series in patients with IPD, and our results may represent 
14 
 
the starting point for an evidence-based approach to the antithrombotic management of these 
subjects. 
CONCLUSIONS  
Our findings suggest that VTE incidence is low in patients with IPD undergoing at risk surgery. 
Moreover, among IPD subjects as well as in the general population, patients at high VTE-risk may 
be identified by the Caprini score. Our data also suggest that mechanical thromboprophylaxis may 
be of benefit in patients with IPD undergoing invasive procedures at VTE-risk and that LMWH 
should be considered for major surgery. Prospective studies are required to further clarify the 
impact of pharmacologic thromboprophylaxis on VTE and bleeding complications in patients with 
IPD undergoing surgery. 
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Table 1. IPD patient characteristics according to type of surgery 
IPD: inherited platelet disorders; IQR: interquartile range; LMWH: low molecular weight heparin; NA: not available; *: in some procedures both 
mechanical and LMWH thromboprophylaxis was employed 
 
Abdominal 
surgery 
(N 72) 
Gynecological 
surgery 
(N 55) 
Orthopedic 
surgery 
(N 41) 
Urological 
surgery 
(N 14) 
Cardiovascular 
surgery 
(N 10) 
Thoracic 
surgery 
(N 9) 
Neuro/spinal 
surgery 
(N 9) 
Age in years, median (IQR) 47 (29-57) 36 (29-45) 42 (24-58) 58 (45-70) 54 (52-65) 37(28-58) 40 (16-76) 
Females, N (%) 38 (54.2) 55 (100) 22 (53.7) 3 (21.4) 6 (60) 2 (22) 3 (30) 
Platelet count before surgery (x10
9
/L)  
median (IQR) 
120 
(65-175) 
56 
(34-162.5) 
139 
(103-191.5) 
75 
(5-90) 
60 
(425-94) 
NA NA 
Malignancy, N (%) 1 (1.4) 2 (3.6) 1 (2.4) 1 (7.1) 2 (20) 3 (33) 1 (11) 
WHO bleeding score, median (IQR) 2 (1-4) 2 (1-2) 2 (1-3) 2 (1-3) 3 (1-3) 2 (1-3) 3 (2-4) 
Caprini score, median (IQR) 2 (1-4) 3 (2-5) 4 (2-7) 3 (2-4) 7 (3-8) 2(1-5) 2 (0-8) 
Caprini class risk, median (IQR) 1 (1-2) 2 (1-3) 2 (1-2) 2 (1-2) 4 (3-4) 2 (1-4) 2 (1-4) 
Use of thromboprophylaxis, N (%) 7 (9) 12 (21.8) 13 (31.7) 7 (50) 0 7 (77) 3(30) 
Mechanical thromboprophylaxis, N (%) *5 (6.9) *7 (12.7) 4 (9.7) 6 (42.9) 0 6 (66) 2(22) 
LMWH thromboprophylaxis, N (%) 3 (4.2) 7 (12.7) 9 (22) 1 (7.1) 0 1 (11) 1 (11) 
Preoperative antihemorrhagic 
prophylaxis, N (%) 
34 (62.5) 27 (49.1) 25 (62) 9 (64.3) 7 (70) 5 (55) 7  (77) 
Any excessive post-surgical bleeding, N 
(%) 
22 (30) 42 (76.5) 5 (12.5) 2 (14.3) 6 (60) 3 (33) 4 (44) 
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Table 2. Differences between surgical procedures carried out with or without LMWH 
thromboprophylaxis. 
 
 
 
LMWH use 
(N=22) 
LMWH non use 
(N=188) 
P value 
Age, median (IQR) 
67 
(79-55) 
42 
(25-54) 
0.01 
Females, N (%)  14 (63.6)  120 (63.8) n.s. 
Platelet count before 
surgery    x 10
9
/L, 
median (IQR) 
158 
(120-287) 
120 
(8-163) 
n.s. 
IPFD, N (%)  12 (54.5)  98 (52.1) n.s. 
COPD, N (%)  2 (9.1)  2 (1.1) n.s. 
Malignancy, N (%)  4 (18.4)  7 (3.2) 0.018 
WHO bleeding score,  
median (IQR) 
2 (0.75-3) 2 (1-3) n.s. 
Caprini score, median 
(IQR) 
8 (5-12) 4 (2-6) 0.02 
Caprini class, 
 median (IQR)  
4 (3-4) 3(2-4) 0.01 
Preoperative 
antihemorrhagic 
prophylaxis, N (%) 
 12 (54.5)  113 (60.1) n.s. 
Any excessive post-
surgical bleeding, N (%) 
 4 (18.2)  46 (25.8) n.s. 
Treatment of post-surgical 
bleeding, N (%) 
 6 (28.6)  49 (27.2) n.s. 
Post-surgical bleeding 
duration, hours, median 
(IQR) 
6 (4-8) 6 (1-6) n.s. 
Failure of post-surgical  
bleeding control, 
 N (%) 
4 (19) 13 (7) n.s. 
Thrombosis, N (%) 0 2 (1) n.s. 
 
IQR: interquartile range, COPD: chronic obstructive pulmonary disease, IPFD: inherited platelet 
function disorders, IPND inherited platelet number disorders; LMWH: low molecular weight 
heparin. 
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FIGURE LEGENDS 
 
Figure 1. Use of thromboprophylaxis in different types of surgery in the IPD population. 
 
Figure 2. Use of LMWH in IPD patients according to VTE risk classes. Use of LMWH in IPD patients 
according to A) Caprini VTE class risk and B) procedure related VTE-risk (* p<0.01 vs high-risk). 
 
Figure 3.  Use of thromboprophylaxis according to date of surgery (*p<0.01 vs 2010-2017). 
Procedures carried out ≤ 1980 were 7 (3.3% of total). 
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SUPPLEMENTAL METHODS 
Study population 
SPATA was a multicenter, international, retrospective observational study including patients with a 
definite diagnosis of IPD established according to well-defined laboratory and/or molecular genetic 
criteria25-27 undergoing surgery 17. IPDs were subdivided into inherited platelet number disorders 
(IPNDs), when low platelet count was the main phenotypic characteristic, and inherited platelet 
function disorders (IPFDs), when platelet dysfunction was the dominant phenotypic feature. 
Patients with acquired platelet disorders of any etiology were excluded 17. 
In the current sub-study we included all the surgical procedures performed in patients for whom 
thromboprophylaxis should have been considered according to current guidelines, including major 
and minor invasive interventions3, 11,28. The decision to apply thromboprophylaxis was made by the 
attending physicians on an individual basis. Patients under 16 years of age were excluded due to the 
lower intrinsic VTE-risk in younger age29, 30. Major surgery was defined as any procedure in which a 
body cavity was entered, a mesenchymal barrier was crossed, a facial plane was opened, an organ 
was removed or normal anatomy was altered while minor invasive procedures were defined as any 
surgical procedure in which only skin, mucous membranes or superficial connective tissue were 
manipulated 17, 28.  Given the significant in situ thrombotic risk of central venous catheter insertion 
interventions 31, these were also considered in the analysis as minor procedures with high local 
thrombotic risk. Dental, ophthalmic, dermatological and endoscopic procedures and minor surgery 
not requiring immobilization were excluded.  
Among the 829 surgical procedures included in the SPATA study, all those potentially amenable to 
thromboprophylaxis were identified 4 and the participating investigators were asked to review their 
records to extract additional data and, when data were not available in the records, to contact the 
surgeon who carried out the intervention or, when this was not possible, the patient or his/her 
relatives. A 48-item structured questionnaire on VTE-risk, thrombotic and bleeding events and 
antithrombotic prophylaxis had to be filled in for each at-risk procedure. Individual bleeding risk was 
estimated according to the type of IPD and previous individual bleeding history as assessed by the 
WHO-bleeding score 17. 
The Institutional Review Board of the coordinating center approved this sub-study (CEAS Umbria, 
Italy, Approval n. 13138/18), each participating center complied with local ethical rules, and all 
patients or their legal representatives signed written informed consent. 
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Thromboembolic risk  
VTE-risk associated with the individual surgical procedures was estimated using the Caprini Score 32, 
a validated method to predict VTE-risk based on clinical and laboratory parameters, such as type of 
intervention, comorbidities, previous VTE and thrombophilia, derived from a prospective study 
including patients undergoing general surgery 33. The enrolled procedures were subdivided into four 
classes of risk depending on the Caprini score (very low risk: 0; low risk: 1-2; moderate risk: 3-4; high 
risk: ≥5). Surgical procedures were also classified according to procedure-related VTE-risk in three 
groups as suggested by the 2008 ACCP guidelines (low risk: minor surgery and interventions not 
requiring patient immobilization; moderate risk: abdominal, thoracic, gynecological and urological 
open surgery; high risk: hip or knee arthroplasty, hip fracture surgery, spinal cord injury and 
procedures associated with high bleeding risk)3. Both the Caprini and the procedure-related VTE-
risk scores were centrally calculated based on the replies given by the participating investigators to 
the 48-item questionnaires.  
 
Thrombotic outcomes 
Thrombotic outcomes were defined as any symptomatic thrombosis (deep venous, including distal, 
and superficial) and/or pulmonary embolism occurring within one month after surgery. Diagnosis 
had to be confirmed using a validated method, including compression ultrasonography (CUS), 
phlebography, contrast enhanced computed tomography or ventilation/perfusion scintigraphy.  
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Supplementary table 1. Characteristics of patients and procedures according to the type of defect. 
 
IPFD 
Number of 
procedures  
(%) 
Age 
median 
(IQR) 
WHO-BS 
bleeding 
score  
median 
(IQR) 
Platelet count 
at surgery 
(x10
9
/L) 
median (IQR) 
Caprini class 
median (IQR) 
Procedure-
related VTE 
risk 
median 
(IQR) 
   Thrombo 
prophylaxis 
(%) 
LMWH (%) 
 
Mechanical 
(%) 
Any excessive 
post-surgical 
bleeding 
(%) 
α2-adrenergic 
receptor defect 
2 (1.8) 58 (58-
59) 1 (1-1) 
163.2(162-
163.2) 3 (3-3) 
1 (1-1) 0 0 0 0 
Combined  /  
granule deficiency 1 (0.9) 43 2 (2-2) NA 4 1  1 (100) 0 1 (100) 1 (100) 
Bernard-Soulier 
Syndrome 
(biallelic) 
11 (10) 53 (46-
56) 3 (2-3) 60 (35.6-66.5) 4 (2-4) 
2 (1-2) 
0 0 0 7 (63) 
Collagen receptors 
defect 
2 (1.8) 47 (38-
47) 2 (2-2) 58 (58-58) 2 (2-3) 
2.5 (2-3) 2 (100) 2 (100) 1 (50) 0 
CalDAG-related 
platelet disorder 
1 (0.9) NA 3 NA 3 2 1 1 (100) 0 0 
Delta granule 
deficiency 
20 (18.2) 50 (30-
57) 3(1-3) NA 3(2-3) 
2 (2-3) 13 (65) 1 (5) 12 (60) 2 (10) 
Gray platelet 
syndrome 
6 (5.5) 60 (28-
69) 2 (2-2) NA 2 (1-3) 
2 (2-2) 2 (33) 1(16.7) 1 (16.7) 2 (33) 
Glanzmann 
thrombasthenia 
33 (30) 49 (37-
60) 3 (1-3) 185(142-212.5) 3 (2-4) 
2 (1-2) 5 (15) 4 (12.1) 1 (3) 10 (30) 
Glanzmann 
thrombasthenia 
variant form 
5 (4.5) 32 (21-
38) 2 (2-3) NA 2 (2-3) 
2 (1-2) 
0 0 0 1 (20) 
Hermansky–Pudlak 
syndrome 
2 (1.8) 52 (52-
52) 2 (2-2) 
197.5 (194-
197.5) 4 (4-4) 
2 (1-2) 0 0 0 1(50) 
P2Y12 deficiency 3 (2.7) NA 2 (2-2) NA 2 (1-2) 2 (2-2) 0 0 0 0 
Primary secretion 
defect 
18 (16.4) 37 (28-
59) 3(2-3) 245 (194-245) 2 (3-2) 
3(3-3) 12 (67) 1 (5.6) 11 (61) 5 (27) 
Platelet-type Von 
Willebrand Disease 
4 (3.6) 31 (23-
58) 3 (3-3) 180 (112-180) 1 (1-1) 
2 (2-2) 1 (25) 1 (25) 0 2 (50) 
Scott syndrome 1 (0,9) 43 NA NA 3 1 0 0 0 0 
Thromboxane A2 
receptor defect 
1 (0.9) 24 2 NA 4 1 (1-1) 0 0 0 0 
Total 110 48 (31-57) 4 (3-4) 
145 
(59 -200) 2 (1-4) 
1 (1-2) 38 (34.5) 12 (10.9) 27 (24.5) 31 (14.7) 
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IPND 
Number of 
procedures  
(%) 
Age, 
median 
(IQR) 
WHO-
BS, 
median 
(IQR) 
Platelet 
count at 
surgery (x 
109/L), 
median 
(IQR) 
Caprini class, 
median (IQR) 
 
Procedure-
related VTE risk 
median (IQR) 
Thrombo 
prophylaxis 
(%) 
LMWH 
(%) Mechanical (%) 
Any 
excessive 
post-
surgical 
bleeding 
(%) 
ACTN1-related 
thrombocytopenia 
5 (5) 54 (19-
64) 2 (1-2) NA 3 (2-3) 
1 (1-2) 0 0 0 0 
ANKRD26-related 
thrombocytopenia 
32 (32) 44 (29-
56) 1 (0-2) NA 3 (2-4) 
2 (1-2) 1 (3.1) 1 (3.1) 0 4(12.5) 
Familial platelet 
disorder and 
predisposition to 
acute 
myelogenous 
leukemia 
4 (4) 26 (21-
57) 2 (0-2) NA 2 (1-3) 
 
 
 
2 (2-3) 1 (25) 1 (25) 1 (25) 3 (75) 
Bernard-Soulier 
Syndrome 
(monoallelic) 
26 (26) 40 (31-
56) 0 (0-2) 
120 (120-
782.5) 2 (1-4) 
2 (2-2) 
3 (11) 3 (11.5) 0 4 (15.4) 
MYH9-related 
disease 
30 (30) 37 (25-
50) 2 (1-2) 
39.5 (34.5-
92.5) 3 (2-4) 
2(1-2) 4 (13.3) 3 (10) 1 (3.3) 8 (26.7) 
TRPM7 channel 
defect 1(1) 34 0 8 4 2 (2-2) 1 1 (100) 1 (100) 0 
TUBB1-related 
thrombocytopenia 
1(1) 33 2 88 3 1 (1-1) 1 1 (100) 0 0 
X-linked 
thrombocytopenia 1(1) 26 2 NA 2 2 (2-2) 0 0 0 0 
Total 100 41 (26-54) 3(1-3) 
88 
(40-120) 2(1-3) 
2 (1-2) 11 10 3 19 
 
WHO-BS: World Health Organization bleeding assessment scale; LMWH: low molecular weight heparin; IPFD: inherited platelet function disorders, 
IPND: inherited platelet number disorders; NA: not applicable, missing data 
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Supplementary table 2. Characteristics of patients with FV Leiden mutation and cancer 
 
 
 F V Leiden Malignancy 
N (% of total) 2 (0.9)               11 (5.2) 
Age median (IQR) 26               59 (55-72) 
Mechanical tromboprophylaxis N 
(%) 
0 (0)                   5 (45) 
LMWH thromboprophylaxis N (%) 0 (0)                  4 (36) 
Pro-hemostatic preoperatory 
prophylaxis N (%) 1 (50)                  6 (54.5) 
Type of surgery N (%)   
    Orthopedic 0 (0)                  1   (9.1) 
    Abdominal 0 (0)                  1   (9.1) 
    Cardiovascular 0 (0)                  2 (18.1) 
    Gynecological 2 (100)                  2 (18.1) 
    Neuro/spine surgery 0 (0)                  1   (9.1) 
    Thoracic 0 (0)                  3   (27.2) 
    Urological 0 (0)                  1   (9.1) 
Post-surgical hemorrhage N (%) 0 (0)                   3  (27) 
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Supplementary table 3. Logistic regression analysis of parameters associated with LMWH use. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LMWH: low molecular weight heparin; WHO-BS: World Health Organization bleeding assessment 
scale. Surgey risk: VTE class of risk according to surgery. 
 
 
 
 
 
 
 OR CI P value 
Gender (female) 0.587 0.117-2.950 0.518 
Age 1.053 1.007-1.100 0.023 
Caprini class of risk   0.002 
Very low risk 0.169 0.016-1.733 0.134 
Low risk 0.066 0.007-0.608 0.016 
Moderate risk 0.060 0.011-0.330 0.001 
High risk 1   
Obesity 0.617 0.129-2.958 0.546 
Surgery   0.680 
Orthopedic 1   
Abdominal 0.152 0.027-0.869 0.034 
Cardiovascular - - - 
Gynecological 1.543 0.253-9.416 0.638 
Neuro/spine 
surgery 
0.161 0.005-4.295 0.295 
Thoracic 0.286 0.015-5.566 0.408 
Urological 0.298 0.020-4.396 0.378 
WHO-BS   0.505 
WHO 0 0.086 0.005-1.435 0.088 
WHO 1 0.870 0.162-4.671 0.871 
WHO 2 0.543 0.090-3.263 0.504 
WHO 3 - - - 
WHO 4 1   
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Supplementary table 4. Logistic regression analysis of the parameters associated with the need 
of emergency treatment of post-surgical bleeding 
 
 OR CI P value 
LMWH use 0.737 0.236-2.302 0.599 
WHO Bleeding 
score 
  
0.002 
WHO 0 0.054 0.005-0.636 0.020 
WHO 1 0.620 0.129-2.2969 0.549 
WHO 2 0.283 0.064-1.250 0.096 
WHO 3 1.239 0.288-5.327 0.773 
WHO 4 1   
Gender (female) 1.210 0.564-2.596 0.625 
IPFD vs IPND 1.070 0.448-2.554 0.879 
Any preoperative 
antihemorrhagic 
prophylaxis 
1.556 0.631-3.836 0.337 
 
LMWH: low molecular weight heparin; IPFD: inherited platelet function disorders; IPND: inherited 
platelet number disorders; WHO-BS: World Health Organization bleeding assessment scale. 
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Supplementary table 5. Logistic regression analysis of predictors of unsuccessful control of 
bleeding  
 OR CI P value 
LMWH use 2.057 0.496-8.536 0.321 
WHO-BS   0.904 
WHO 0 - - - 
WHO 1 0.298 0.020-4.447 0.380 
WHO 2 0.407 0.036-4.567 0.466 
WHO 3 0.551 0.051-6.001 0.625 
WHO 4 1   
Gender (female) 0.355 0.114-1.101 0.625 
IPFD vs IPND 6.760 1.139-40.123 0.879 
Any prophylaxis 0.524 0.127-2.170 0.337 
Caprini class of risk   0.449 
Very low risk 1   
Low  risk 0.403 0,049-3,320 0,398 
Moderate risk 0.944 0.143-6.205 0.952 
High risk 1.597 0.277-9.209 0.601 
 
Logistic regression. LMWH: low molecular weight heparin; IPFD: inherited platelet function 
disorders; IPND: inherited platelet number disorders; WHO-BS: World Health Organization bleeding 
assessment scale. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
